Zai Lab Limited
ZLABHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Zai Lab Limited focuses on Biotechnology services and products. Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and. At a $2.85B market cap, Zai Lab Limited ranks as a mid-cap company within healthcare. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Market Cap
$2.85B
Beta
0.83
P/E (TTM)
—
P/E (Fwd)
-12.04
EPS (TTM)
$-1.70
EPS (Fwd)
$-2.11
ROE
-26.9%
ROA
-14.8%
Cash
$617.5M
Total Debt
$254.6M
Free CF
-$84.0M
52W Change
-7.6%
Annual Financials
Cash vs Debt
Where ZLAB stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ZLAB finished 26.06% above its 150-day moving average ($20.07) and 28.10% above its 200-day moving average ($19.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZLAB overbought or oversold?
At the September 2, 2026 close, ZLAB's RSI(14) was 48.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $617.5M in cash and $254.6M in debt, ZLAB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$84.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -26.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $215.0M (2022) to $460.2M (2025), reflecting a 114% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Zai Lab Limited and its sector.